Polaris Partners

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Contact Networks offers Enterprise Relationship Management (ERM) software solutions designed to help professional services firms maximize the value of their relationship networks for business development. Their flagship product, ContactNet, is an automated search application that quickly identifies employees with strong relationships to a client or prospect. Based in Boston, MA, Contact Networks was acquired by Thomson Reuters in 2007.

Founded in 2018, Tausight is a technology company based in Sudbury, Massachusetts with an additional office in San Francisco. It specializes in developing software to reduce healthcare cyber incidents involving patient data theft.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Founded in 2020, 76Bio is a biotechnology company dedicated to developing innovative therapies for patients with life-threatening diseases. It specializes in pioneering targeted protein degraders.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Founded in 2018, Tausight is a technology company based in Sudbury, Massachusetts with an additional office in San Francisco. It specializes in developing software to reduce healthcare cyber incidents involving patient data theft.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Amagma Therapeutics is a biotechnology company founded in 2019 and based in Waltham, Massachusetts. The company focuses on the discovery and development of antibody therapeutics aimed at addressing inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma's therapies target overactive extracellular proteases, which lead to tissue damage and contribute to widespread inflammatory responses. By developing these innovative treatments, Amagma aims to enhance therapeutic efficacy while ensuring patient safety in the management of human diseases linked to enzyme dysfunction.

1366 Technologies Inc., established in 2008, specializes in the development, manufacturing, and supply of silicon wafers for solar cell applications. Based in Bedford, Massachusetts, with additional facilities in Shanghai, China, and Mumbai, India, the company produces both 3D direct wafers and conventional silicon solar wafers. Through strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd., 1366 Technologies supplies its products to major players in the solar industry. Its proprietary technology enables the production of silicon wafers directly from molten silicon, resulting in lower costs, reduced energy requirements, and improved uniformity compared to traditional methods. This allows businesses to create more efficient and cost-effective solar cells.

OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Founded in Vermont in 2012, Caledonia Spirits is a craft distillery dedicated to supporting local agriculture. It produces gin and vodka using locally sourced ingredients like grains and honey, aiming to add value to the work of Vermont farmers while honoring traditional spirits-making techniques.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Drizly is an online alcohol marketplace and liquor retail platform that enables on-demand delivery and shipping of beer, wine and spirits. It partners with retailers to bring their inventory online across 235 markets, offering a broad selection to consumers of legal drinking age and a transparent, personalized shopping experience. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly helps retailers reach new customers and gain market and customer insights, supporting growth in sales. The platform also supports ordering of beverages along with mixers and garnishes, enabling customers to order without visiting a store.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Twistlock Inc. is a provider of comprehensive security solutions for cloud-native applications, focusing on Docker container security for DevOps environments. Founded in 2015, the company offers a suite of products designed to protect applications throughout their development lifecycle and into production. Its flagship product, Twistlock, enables developers and security teams to safeguard container-based applications with features such as vulnerability management, compliance, access control, and runtime defense. Twistlock's Trust component scans images and registries to identify vulnerabilities and configuration errors, while Twistlock Runtime delivers real-time threat protection and policy enforcement. The company is trusted by a significant portion of the Fortune 100 and is headquartered in Portland, Oregon, with additional offices in New York City, Baton Rouge, London, and Herzliya, Israel. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, Inc.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, that focuses on designing and developing innovative therapeutic products with a unique delivery technology. Established in 2016, the company specializes in enabling ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract without the need for encapsulation. Suono Bio aims to transform the treatment landscape for difficult-to-treat diseases, particularly those mediated by inflammatory processes, by facilitating effective therapy delivery that enhances patient recovery from gastrointestinal conditions.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Neuronetics is a medical technology company that designs, develops, and markets non-invasive therapies for psychiatric disorders. Its flagship product, NeuroStar Advanced Therapy System, uses transcranial magnetic stimulation to treat adult patients with major depressive disorder in office-based settings.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Twistlock Inc. is a provider of comprehensive security solutions for cloud-native applications, focusing on Docker container security for DevOps environments. Founded in 2015, the company offers a suite of products designed to protect applications throughout their development lifecycle and into production. Its flagship product, Twistlock, enables developers and security teams to safeguard container-based applications with features such as vulnerability management, compliance, access control, and runtime defense. Twistlock's Trust component scans images and registries to identify vulnerabilities and configuration errors, while Twistlock Runtime delivers real-time threat protection and policy enforcement. The company is trusted by a significant portion of the Fortune 100 and is headquartered in Portland, Oregon, with additional offices in New York City, Baton Rouge, London, and Herzliya, Israel. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, Inc.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Drizly is an online alcohol marketplace and liquor retail platform that enables on-demand delivery and shipping of beer, wine and spirits. It partners with retailers to bring their inventory online across 235 markets, offering a broad selection to consumers of legal drinking age and a transparent, personalized shopping experience. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly helps retailers reach new customers and gain market and customer insights, supporting growth in sales. The platform also supports ordering of beverages along with mixers and garnishes, enabling customers to order without visiting a store.

Qstream, Inc. is a software company that specializes in developing a mobile sales acceleration platform designed to enhance job proficiency and influence behavior within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves clients across various sectors, including technology, financial services, and life sciences. The company operates engineering facilities in Dublin, Ireland, and Hood River, Oregon, while maintaining sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco. Qstream's micro-learning platform enables organizations to manage and measure the human aspects of sales performance, providing analytics-driven insights that facilitate team excellence.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Founded in 2014, Sofregen Medical specializes in developing silk protein-based biomaterials for use in aesthetic procedures and surgeries. The company aims to enhance soft tissue regeneration, restoring function and cosmetic appearance for medical and aesthetic patients worldwide.

B12 operates a human-assisted AI platform that streamlines website design processes. It offers Orchestra, an online tool integrating with third-party platforms like e-commerce and blogging services, alerting experts to web design quality issues.